As gene therapy progresses toward broader clinical and commercial success, the industry is shifting from treating rare conditions to those of larger populations. This requires scalable solutions for process intensification. In this webinar, we discuss scale-up development for a common viral vector in gene therapy, lentivirus, using the VirusExpress™ Lentiviral Production Platform in Mobius® single-use bioreactors. We highlight critical considerations when moving from bench-scale to clinical scale process design with manufacturability in mind to ensure commercial readiness. Finally, we’ll review the significant benefits of implementing a templated manufacturing process.
In this webinar, you will learn:
Senior Scientist , Virus & Gene Therapy Bioprocessing
Eva received her B.S. in chemistry and biological sciences from the University of California, Irvine. Since graduating, she has held roles in multiple organizations, conducting pre-clinical, process development, engineering, and manufacturing activities for monoclonal antibody and viral vector therapeutics. Within MilliporeSigma, she leads a team responsible for all upstream and downstream scale-up R&D to develop best-in-class lentiviral and AAV manufacturing products and templates.
To continue reading please sign in or create an account.Don't Have An Account?